A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

Demand for popular GLP-1 drugs has skyrocketed, but while many can see health benefits — such as weight loss and blood sugar ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

As Hain Celestial gears up to become a “pure play” food and beverage supplier, the company sees opportunities linked to GLP-1 ...

The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound ... For Zepbound, which is approved for weight loss, revenue of $1.9 billion is a bit closer to expectations of $2.1 billion ...

It fell last week after the company released updated guidance, with revenue for its GLP-1 drugs projected ... For Zepbound, which is approved for weight loss, revenue of $1.9 billion is a bit ...

Sales of Danone’s popular yogurt brands are finding a more prominent place on the menu with consumers who are eating less as a result of using Ozempic and other popular weight-loss drugs.

Discover how GLP-1 weight loss medications like Ozempic and Wegovy are linked to reduced risks of dementia heart disease and more—alongside potential side effects to consider ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

If you've been around long enough, you will encounter some bumps in the road. This is true for The Hershey Company ( HSY ...